Timothy Whitten is the former President and CEO of Insmed, a pharmaceutical company known for its innovative drugs. He joined Insmed in December 2010 after successfully leading Transave as its CEO since 2006. Before that, he built his career at...

Timothy Whitten is the former President and CEO of Insmed, a pharmaceutical company known for its innovative drugs. He joined Insmed in December 2010 after successfully leading Transave as its CEO since 2006. Before that, he built his career at Bristol-Myers Squibb, where he spent 16 years in various leadership roles, including overseeing the launch of Taxol, a widely used oncology drug. He holds an MBA from the University of Virginia and a pharmacy degree, graduating Magna Cum Laude from West Virginia University. Whitten's tenure at Insmed included overseeing significant clinical trials and setting key corporate objectives. His leadership style emphasizes performance metrics and aligning employee incentives with company goals. Although he resigned in 2012, his impact on Insmed’s trajectory continues to influence the company’s current operations.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Insmed CEOs

I

Timothy Whitten

Ex-CEO of Insmed

Education

M.B.A. from University of Virginia

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1957 - 68 years ago

CEO of Insmed for

1 year 9 months (Dec 2010 - Sep 2012)

Previous Experience

President and Chief Executive Officer of Transave

Rivals

Competitors/colleagues of Timothy Whitten

Holdings

See how much did Timothy Whitten make over time.

During his career, Timothy Whitten has seen fluctuations in his wealth primarily tied to Insmed's stock. Notably, his insider trading revealed peaks in stock trading activity in 2019 and 2020, indicating times when his wealth was significantly tied to his...

During his career, Timothy Whitten has seen fluctuations in his wealth primarily tied to Insmed's stock. Notably, his insider trading revealed peaks in stock trading activity in 2019 and 2020, indicating times when his wealth was significantly tied to his executive role. September 2019 reported over $188K in transactions, with a gradual increase to $376K by December of the same year. This trend continued, peaking at nearly $751K in August 2024. His trading patterns highlight the relationship between his financial interests and Insmed’s performance, showing both the risks and rewards that come with leading a biotech company.

Mar 18, 2025

I

shares

INSM @ $76.99

Insider Trading

See recent insider trades of Timothy Whitten.

INSM

$21.79K

INSM at $2.91/share

Jun 1, 2012

Purchase

INSM

$16.45K

INSM at $6.58/share

Mar 30, 2011

Purchase

Compensation History

See how much did Timothy Whitten make over time.

In terms of compensation, Timothy Whitten's financial package reflected his responsibilities as CEO of Insmed. For 2011, he earned a base salary of $425,000 and was awarded a bonus of $106,250, which was 25% of his salary. This was tied to his performance and the company’s corporate objectives. The compensation also included significant stock awards, valued at over $1.3 million, highlighting the significant equity-based incentives tied to his leadership role. His strategy focused on aligning executive pay with company performance to motivate and retain key talent, a common practice in the biotech industry.

Year

2012

Total Compensation

$500.00K

Salary

$400.00K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate highly qualified executives, aligning their interests with those of shareholders through performance-based compensation.

Bonus

$100.00K

Board Justification

The bonus is based on the achievement of specific performance metrics set by the Board for the fiscal year 2012, which include milestones related to clinical trials and corporate objectives.

Other

$0.00

Board Justification

No additional compensation was reported outside of salary and bonus.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2012 as the focus was on performance-based cash bonuses and salary.

Performance Metrics

The performance metrics for 2012 included successful completion of clinical trial milestones and maintaining appropriate capitalization.

Other Insmed CEOs

Here are other CEOs of Insmed

Dr. Geoffrey Allan

Ex-CEO of Insmed

August 2005 - June 2009

William Lewis

Founder and Ex-CEO of Insmed

September 2012 - December 2017